Localized Therapeutics for the Treatment of Gastrointestinal Disorders

Localized Therapeutics for the Treatment of Gastrointestinal Disorders

The purpose of this study is to determine the patient preference for a biocompatible thermosensitive solution-gel versus water or saline (liquid) enema. The thermosensitive solution-gel is comprised of poloxamer, an inactive compound that is designated as GRAS (generally recognized as safe) by FDA. It could subsequently be used as a medium for drug delivery. The poloxamer (gel) is administered to study participants in order to assess preference and proximal distribution.

Inclusion Criteria:

• Generally healthy
• Age 18 to 70 years old
• Non-pregnant

Exclusion Criteria:

• GI complaints
• Pregnancy
• Patients with previous colonic surgery or current bowel injury or obstruction
• Allergies to contrast